Cite

HARVARD Citation

    Yucebay, F. et al. (2019). Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience. Leukemia & lymphoma. 60 (9), pp. 2223-2229. [Online]. 
  
Back to record